紫杉醇联合替吉奥胶囊治疗晚期胃癌的临床观察

Clinical study of paclitaxel combined with S-l capsule in the treatment of patients with advanced gastric cancer

目的观察紫杉醇联合替吉奥胶囊(维康达)方案治疗晚期胃癌的临床疗效及不良反应。方法 46例晚期胃癌患者采用以下方案化疗:替吉奥胶囊每天80 mg/m2,分2次,餐后口服,d1～d14;紫杉醇60 mg/m2,d1、d8、d15,静脉滴注3 h。28 d为1个周期,至少完成2个周期。按RECIST1.1标准评价客观疗效和不良反应。结果 46例患者均可以评价疗效。CR 3例(6.5%),PR 18例(39.1%),SD 14例(30.4%),PD 11例(23.9%),RR 45.6%,DCR 76.0%。中位疾病进展时间(mT-TP)为9.5个月,中位生存期(MST)为12.6个月。不良反应主要是骨髓抑制、胃肠道反应、脱发及口腔黏膜炎。结论紫杉醇联合替吉奥方案治疗晚期胃癌的疗效较好,不良反应可以耐受,值得进一步研究应用。

Objective To observe the efficacy and toxicity of paclitaxel combined with S-1 capsule in the treatment of advanced gastric cancer patients.Methods A total of 46 patients with advanced gastric cancer were treated with chemotherapy of intravenous paclitaxel 60 mg/m2 on days 1,8,15 and S-1 capsule 80 mg/m2 twice daily for 14 days.The chemotherapy was repeated every 28 days.All patients received 2 cycles at least.Efficacy and toxicity were evaluated according to the RECIST 1.1 standard.Results Of the 46 patients,3（6.5%） got complete remission（CR）,18（39.1%） partial remission（PR）,14（30.4%）stable disease（SD）,and 11（23.9%） progression disease（PD）.The total response rate was 45.6%.The disease control rate（DCR）was 76.0%.The median time to progression（mTIP）was 9.5 months.The median survival time（MST） was 12.6 months.The major toxic reactions included leucopenia,nausea,vomiting and neurosensory abnormality.Conclusion Paclitaxel combined with S-1 is effective and tolerable in the treatment of patients with advanced gastric cancer.